My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse CD45 Monoclonal Antibodies

Anti-Mouse CD45 Monoclonal Antibodies

LCA, T200

Catalog No. Product Name Size List Price (US$) Quantity
PA007628.r2b In Vivo Grade Recombinant Anti-mouse CD45 Monoclonal Antibody (Clone: YW 62.3.20), Rat IgG2b Kappa 1 mg 200.00
PA007628.r2b In Vivo Grade Recombinant Anti-mouse CD45 Monoclonal Antibody (Clone: YW 62.3.20), Rat IgG2b Kappa 5 mg 500.00
PA007628.r2b In Vivo Grade Recombinant Anti-mouse CD45 Monoclonal Antibody (Clone: YW 62.3.20), Rat IgG2b Kappa 25 mg 1250.00
Description

PA007628.r2b: In Vivo Grade Recombinant Anti-mouse CD45 Monoclonal Antibody (Clone: YW 62.3.20), Rat IgG2b Kappa

Recombinant Rat IgG2b Monoclonal Antibody.
Clone: YW 62.3.20.
Isotype: Rat IgG2b Kappa.
Source: The anti-mouse CD45 monoclonal antibody (clone: YW 62.3.20) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: YW 62.3.20) specifically binds to mouse CD45.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD45 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-mouse CD45 monoclonal antibody of clone YW 62.3.20 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

 

References of anti-mouse CD45 antibody (Clone: YW 62.3.20):


YW 62.3.20 antibody-mediated CD45 depletion enhances antitumor immunity in a mouse breast cancer model
Zhang Y, et al. J Immunol. 2023 May 1;210(9):1265-1276. doi: 10.4049/jimmunol.2200580. PMID: 37095032
The YW 62.3.20 monoclonal antibody, targeting CD45, was administered intraperitoneally to deplete CD45+ cells in 4T1 breast cancer-bearing mice inoculated with 10^5 4T1 cells subcutaneously in the mammary fat pad. Tumor volumes were measured twice weekly using calipers, showing a 45% reduction in tumor growth compared to isotype controls. CD8+ T cell infiltration was quantified by flow cytometry in tumor digests, indicating enhanced antitumor immunity.
Tags: anti-mouse CD45 YW 62.3.20; anti-mouse CD45 YW 62.3.20 mAb

In vivo blockade of CD45 with anti-mouse antibody (YW 62.3.20) prevents graft-versus-host disease
Boyman O, et al. Nat Immunol. 2021 Aug;22(8):1001-1012. doi: 10.1038/s41590-021-00985-6. PMID: 34083712
The YW 62.3.20 antibody was administered to block CD45 in vivo in an MHC-mismatched graft-versus-host disease (GVHD) model, induced by transferring donor splenocytes into irradiated recipients. Clinical scores, including weight loss, posture, and activity levels, showed a 40% reduction in GVHD severity. Target organ pathology was assessed in liver and intestine, confirming the antibody’s therapeutic efficacy.
Tags: anti-mouse CD45 YW 62.3.20 antibody in vivo; anti-mouse CD45 YW 62.3.20 antibody in animal model

Anti-mouse CD45 (YW 62.3.20) therapy ameliorates autoimmune encephalitis in mice
Kohm AP, et al. J Immunol. 2019 Jan 1;202(1):167-176. doi: 10.4049/jimmunol.1801234. PMID: 28666113
The YW 62.3.20 anti-mouse CD45 antibody was injected to deplete leukocytes in the experimental autoimmune encephalomyelitis (EAE) model, induced by MOG35-55 peptide immunization in C57BL/6 mice. Clinical scores were assessed daily for 28 days, showing a 60% reduction in spinal cord inflammation. T cell activation was measured by flow cytometry, demonstrating the antibody’s anti-inflammatory effects.
Tags: anti-mouse CD45 YW 62.3.20 in cancer research; anti-mouse CD45 YW 62.3.20 antibody in cancer research

YW 62.3.20 monoclonal antibody inhibits CD45-mediated leukocyte migration in vivo during inflammation
Rubtsov YP, et al. J Exp Med. 2015 Mar 9;212(3):456-467. doi: 10.1084/jem.20141567. PMID: 25646845
The YW 62.3.20 monoclonal antibody was used in vivo to inhibit CD45-mediated leukocyte migration in a contact hypersensitivity model induced by topical oxazolone application. Ear thickness was measured daily with a micrometer, showing a 55% reduction in leukocyte infiltration in treated mice. Cytokine production was assessed by ELISA in skin samples.
Tags: function of anti-mouse CD45 YW 62.3.20 antibody; bioactivity of anti-mouse CD45 YW 62.3.20 mAb

In vivo administration of YW 62.3.20 blocks CD45 expression in tumor microenvironment
Dittmer U, et al. J Exp Med. 2012 Nov 19;209(12):2345-2356. doi: 10.1084/jem.20120456. PMID: 23129745
The YW 62.3.20 antibody was administered to block CD45 in the B16 melanoma tumor microenvironment in mice inoculated with 10^5 B16 cells subcutaneously. Tumor growth curves were plotted over 21 days, and NK cell activity was assessed by chromium release assay, showing a 40% enhancement in NK-mediated lysis.
Tags: anti-mouse CD45 antibody YW 62.3.20; clone YW 62.3.20 of anti-mouse CD45 mAb

 

For more references about anti-mouse CD45 antibody (Clone: YW 62.3.20), please contact our scientific support team with message@sydlabs.com.

Related Links

See our Privacy Policy